Key Highlights

  • Liminatus Pharma (NASDAQ:LIMN) is quoted at USD 2.98 pre-market on Tuesday, November 10, 2026, up 9.96% from a calculated prior close of USD 2.71, with no catalyst dated November 9 or 10 located.
  • A November 3, 2026 8-K revealed a private Placement of 260,001 shares at USD 2.50 for gross proceeds of USD 650,002.50, with closing expected on or about November 20, 2026.
  • The October 26 snapshot put Market Capitalisation at USD 4.24 million on 1.34 million shares, with a 52-week range of USD 2.905 to USD 141.50.
  • The company recorded a net loss of USD 12.52 million and regained Nasdaq bid price compliance on September 29, 2026, following a 1-for-50 reverse split announced in August 2026.

Drivers Behind Liminatus Pharma's Pre-Market Move (+9.96%)

The pre-market price of USD 2.98 is 9.96% above a calculated prior close of USD 2.71, which is simple arithmetic on the two published figures, a gain of roughly USD 0.27. No release dated November 9 or November 10, 2026 was located, so no catalyst can be named. The newest filing found is the 8-K dated November 3, 2026, in which the company agreed to sell 260,001 shares at USD 2.50 to a non-U.S. investor. At USD 2.98 the stock sits 19.2% above that placement price, a calculated figure. According to the 8-K the shares are unregistered, and a resale registration is due within 60 days of closing, which is expected on or about November 20, 2026.

Why Post-Split Biotechs Often Jump Without Headlines

As general context, a reverse split reduces the share count and lifts the quoted price without changing the value of a holding, and many post-split stocks drift lower as holders sell. Liminatus completed a 1-for-50 split after a Nasdaq delisting notice in May 2026, and regained compliance with the minimum bid rule on September 29, 2026. With only 1.34 million shares outstanding, a few thousand shares can move the price 10%. Private placements priced near the market add Supply once resale registrations take effect, which can weigh on a rally. Traders also buy stocks rebounding from lows, and the 52-week low of USD 2.905 sits close to the current quote. A stock down 97.9% from its peak may also see short covering when sellers step back, which can produce double-digit moves on tiny Volume with no news at all.

Valuation, Liquidity and Risks for Liminatus Pharma (NASDAQ:LIMN)

At USD 2.98 the calculated Market Value is about USD 4.0 million on 1.34 million shares, against a net loss of USD 12.52 million, meaning the annual loss is roughly three times the market value. The shares are 97.9% below their 52-week high of USD 141.50, a calculated figure that reflects the collapse after adjusting for the split. Volume was only 9,816 shares on October 26, 2026, when the stock closed at USD 3.16, up 7.48%, before slipping 10.76% after hours to USD 2.82. Dilution, further Nasdaq deficiency notices and wide pre-market spreads are the main hazards, and a Reversal at the 9:30 a.m. ET open is possible. Pre-market sessions run from 4:00 a.m. to 9:30 a.m. ET, when quotes may reflect only a handful of orders. The company must keep its bid price above USD 1.00 to retain its Nasdaq listing, and a second deficiency would revive delisting risk after the May 2026 notice. Cash was not shown in the published snapshot, so the funding runway cannot be confirmed here. None of this suggests the gain will hold.

Where Things Stand

Liminatus Pharma (NASDAQ:LIMN) is up 9.96% pre-market, with no catalyst identified in published reporting for November 9 or 10, 2026. The latest known event is the November 3 private placement at USD 2.50 a share. A USD 4.0 million market value and thin volume mean the quote can swing sharply.